Proof of Safety and Activity Demonstrated in Phase II Curaxin CBLC102 Trial Establishes Path to Clinic for Next Generation Lead Molecule Curaxin CBLC137; New Mechanistic Discoveries Enable Optimal Design of Treatment Regimens and Potential Combination Therapies

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that the Company will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York City, November 10-12, 2008. The conference will be held at The New York Palace Hotel. Management will be available to meet with investors or licensing partners November 10-11.

Suggests Potential Use as Chemotherapy Adjuvant

Cleveland BioLabs, Inc. (CBLI - News) today announced results of a series of studies demonstrating Protectan CBLB612's ability to substantially reduce myelosuppression (the most common rate limiting adverse effect of chemotherapy) caused by a widely used chemotherapeutic drug, cyclophosphamide (Cytoxan, Neosar, CTX).

Cleveland BioLabs, Inc. (CBLI - News) today announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS).

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that the Company is scheduled to present at the Maxim Group Growth Conference in New York City on Tuesday, October 7, 2008. The conference will be held at the Grand Hyatt New York Hotel.

Recently Awarded $13.3 Million BARDA Development Contract for Protectan CBLB502

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that it will present Protectan CBLB502 at the 2008 Biomedical Advanced Research and Development Authority (BARDA) Stakeholders Workshop and Industry Day, September 24-26, in Washington, DC.

(Biomedical Advanced Research and Development Authority of the Department of Health and Human Services - BARDA)

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) has awarded the Company a contract under the Broad Agency Announcement titled, "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation," for selected tasks in the advanced development of Protectan CBLB502. The total contract value including all milestone-based options is $13.3 million over a three-year period, with the first year's award of $3.4 million, commencing September 16, 2008.

... for Protectan CBLB502 Research in Mitigation of Radiation Damage

Supports Investigation of Ability to Reduce Occurrence and Severity of Thrombocytopenia and Improve Recovery Time

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that it has been awarded a $774,183 grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic (blood/bone marrow) damage from radiation exposure.

Potential Application for Battlefield and Natural Disaster Conditions

Cleveland BioLabs, Inc. (CBLI - News) and founding partner Cleveland Clinic reported today that CBLI's lead product, Protectan CBLB502, currently being developed as a radioprotectant and radiomitigator, demonstrated efficacy in animal models of tourniquet injury. This finding is the result of pre-clinical studies funded by a grant from the Department of Defense to research the use of Protectans in tourniquet and other ligation-reperfusion battlefield injuries, where blood flow is stopped and then restored after a prolonged period of time.

Cleveland BioLabs, Inc. (CBLI - News) announced today the allowance from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials in human volunteers with Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS).

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that its first patent for Protectan CBLB502 was granted by the Eurasian Patent Organization (EAPO), which includes nine member countries. This patent covers the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502.

Cleveland BioLabs has filed over twenty patent applications in the U.S. and internationally, around various properties of Protectan CBLB502 and related compounds, including methods of use and composition of matter. Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, noted that the EAPO patent was the first of several expected approvals. "We have been progressing well with patent examination in various geographies and we hope to receive the first of our U.S. patents related to method of use for Protectan CBLB502 in the coming months."

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News), announced today that it has fully enrolled its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer.

This open label trial is evaluating the safety and efficacy of Curaxin CBLC102 for use in treating patients with hormone-refractory metastatic prostate cancer. Curaxins have multiple mechanisms of action, including simultaneous activation of p53 and inhibition of NF-kappaB, which are frequently deregulated in cancer. Compounds that target p53 or NF-kappaB independently have been validated as cancer therapies; however, Curaxins are the only compounds currently known to CBLI that simultaneously target both pathways.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that Buyins.net initiated coverage on the Company after releasing the latest short sale data through May 2008.

The Buyins.net report stated that the total aggregate number of CBLI shares shorted between July 2006 and May 2008 is approximately 2.5 million shares. The report also stated that the CBLI SqueezeTrigger price of $7.41 is the volume weighted average short price of all short selling in CBLI.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that the Company has been featured in "Gene Marcial's 7 Commandments of Stock Investing," recently published by FT Press. Gene Marcial is a senior writer and columnist at BusinessWeek where he writes the column "Inside Wall Street."

Cleveland BioLabs was cited as one of "several little-known biotechs that have outscored their peers" under the chapter titled, "Commandment 6: Don't Fear The Unknown" of "Gene Marcial's 7 Commandments of Stock Investing." The chapter includes a brief summary by the author of Cleveland BioLabs' history and stock price from its IPO in July 2006 through early 2008.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that Chief Executive Officer and President, Michael Fonstein, Ph.D. and Chief Scientific Officer, Andrei Gudkov, Ph.D, D. Sci. shared 2008 highlights and milestones at the Company's annual meeting today.

Dr. Fonstein reviewed several of the Company's recent achievements including:

Cleveland BioLabs, Inc. hosted a conference call today recapping recent achievements, as well as providing an update on the Company's development strategy and timeline.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that it will host a conference call at 10:00 a.m. EDT on April 17, to recap recent achievements and provide an update on the Company's development strategy and timeline.

Interested parties may participate by dialing 877-407-8031 (US) or 201-689-8031 (International) approximately five to ten minutes before the call start time. A live Webcast of the conference call will be available on the Cleveland BioLabs Web site at www.cbiolabs.com.

A replay of the call will be available starting on April 17, 2008, at 1:00 p.m. EDT through April 24, 2008 at 11:59 p.m. EDT. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 286 and conference ID number 281842. An archived Webcast of the conference call will be available on the Cleveland BioLabs Web site at www.cbiolabs.com.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that Daniel Mallin, Ph.D. and Stephen Brozak of WBB Securities, LLC have updated coverage on the Company.

The WBB Securities report, dated April 11, 2008, assigned a Strong Buy rating to the Company, and reiterated a 12-month target price of $13.00. The report's introduction stated, "In the past eight days, three significant events have taken place that validate CBLI's science, underscore the company's viability and improve the company's outlook." The report then summarized these events.

Interested parties should contact WBB Securities for more information about the report. For more information on WBB Securities, please visit: www.wbbsec.com.

Department of Defense Recently Awarded $8.9 Million Development Contract for Protectan CBLB502

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that Science, the world's leading journal of original scientific research, global news, and commentary, has published breakthrough findings by Cleveland BioLabs researchers regarding Protectan CBLB502's radioprotective abilities, titled, "An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models." Cleveland BioLabs's paper is the first Science publication on radioprotection in more than three decades.